Rexahn Pharma (RNN) Tops Q3 EPS by 1c

Rexahn Pharma (NYSE: RNN) reported Q3 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03).

"Rexahn made important progress during the third quarter presenting new interim clinical data for Supinoxin and RX-3117 at an international medical conference,” said Peter D. Suzdak, Ph.D., Chief Executive Officer. “We were particularly excited to see that these compounds appear to be safe and well tolerated in ongoing clinical studies and show encouraging early signs of clinical efficacy exhibited as stable disease or in some cases, tumor regression. Given that these are very sick patients with advanced disease that have been heavily pre-treated and have previously failed other forms of therapy, we are especially pleased to observe potential efficacy signals at this stage. Rexahn is committed to developing novel, highly targeted cancer treatments that may bring meaningful quality of life improvements for patients and their families and we look forward to continuing to advance our next generation cancer programs through clinical development.”

For earnings history and earnings-related data on Rexahn Pharma (RNN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c